Search results for "Immunosuppressive Agents"

showing 10 items of 280 documents

Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease.

2017

Background Inhibitory antibodies towards enzyme replacement therapy (ERT) are associated with disease progression and poor outcome in affected male patients with lysosomal disorders such as Fabry disease (FD). However, little is known about the impact of immunosuppressive therapy on ERT inhibition in these patients with FD. Methods In this retrospective study, we investigated the effect of long-term immunosuppression on ERT inhibition in male patients with FD (n = 26) receiving immunosuppressive therapy due to kidney (n = 24) or heart (n = 2) transplantation. Results No ERT-naive transplanted patient (n = 8) developed antibodies within follow-up (80 ±72 months) after ERT initiation. Seven (…

0301 basic medicineAdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyAdolescentmedicine.medical_treatmentGastroenterology03 medical and health sciencesYoung Adult0302 clinical medicineMaintenance therapyInternal medicineInternal MedicineMedicineHumansEnzyme Replacement TherapyRetrospective StudiesKidneybusiness.industrynutritional and metabolic diseasesImmunosuppressionEnzyme replacement therapyMiddle Agedmedicine.diseaseFabry diseaseAntibodies NeutralizingKidney TransplantationTacrolimusTransplantation030104 developmental biologymedicine.anatomical_structureImmunologyPrednisoloneFabry DiseaseHeart Transplantationbusiness030217 neurology & neurosurgeryImmunosuppressive Agentsmedicine.drugJournal of internal medicine
researchProduct

Regulatory T cells and vaccine effectiveness in older adults. Challenges and prospects

2021

Since the discovery of lymphocytes with immunosuppressive activity, increasing interest has arisen in their possible influence on the immune response induced by vaccines. Regulatory T cells (Tregs) are essential for maintaining peripheral tolerance, preventing autoimmune diseases, and limiting chronic inflammatory diseases. However, they also limit beneficial immune responses by suppressing anti-infectious and anti-tumor immunity. Mounting evidence suggests that Tregs are involved, at least in part, in the low effectiveness of immunization against various diseases where it has been difficult to obtain protective vaccines. Interestingly, increased activity of Tregs is associated with aging, …

0301 basic medicineImmunologychemical and pharmacologic phenomenaInflammationT-Lymphocytes RegulatoryAutoimmune DiseasesOlder populationImmunomodulation03 medical and health sciences0302 clinical medicineImmune systemImmunitymedicineAnimalsHumansImmunologic FactorsImmunology and AllergyAgedAged 80 and overInflammationPharmacologyVaccinesbusiness.industryVaccinationAge FactorsMembrane ProteinsPeripheral toleranceMiddle AgedVaccination030104 developmental biologyImmunization030220 oncology & carcinogenesisChronic DiseaseImmunologymedicine.symptomOlder peoplebusinessImmunosuppressive AgentsInternational Immunopharmacology
researchProduct

Early inflammatory players in cutanous fibrosis.

2017

Systemic sclerosis (SSc) is one of the most complex systemic autoimmune diseases with multi-organ involvement and heterogeneous clinical manifestations. The exact etiology of SSc is still unknown. However, identified target structures are components of endothelial cells, the innate/adaptive immune systems and fibroblasts, resulting in the hallmarks of the disease in form of inflammation/autoimmunity, vasculopathy and fibrosis of the skin and internal organs. There has been a large body of evidence that the adaptive immune system with autoreactive T and B cells producing autoantibodies plays a central role in the pathogenesis of SSc but the role of earlier pathogenic processes involving the …

0301 basic medicineInflammationAutoimmunityDermatologyBiologymedicine.disease_causeBiochemistryAutoimmunity03 medical and health sciences0302 clinical medicineImmune systemmedicineLeukocytesHumansPlatelet activationskin and connective tissue diseasesMolecular BiologyAutoantibodiesSkinAutoimmune diseaseInflammationImmunity CellularInnate immune systemScleroderma Systemicintegumentary systemInnate lymphoid cellEndothelial CellsFibroblastsmedicine.diseaseAcquired immune systemPlatelet ActivationFibrosisImmunity Innate030104 developmental biology030220 oncology & carcinogenesisImmunologymedicine.symptomImmunosuppressive AgentsJournal of dermatological science
researchProduct

Reply to Comment on: 'Corneal confocal scanning laser microscopy in patients with dry eye disease treated with topical cyclosporine'

2017

Reply to Comment on: ‘Corneal confocal scanning laser microscopy in patients with dry eye disease treated with topical cyclosporine’

0301 basic medicineLaser Microscopymedicine.medical_specialtygenetic structuresConfocalAdministration TopicaleducationDry Eye SyndromesOphthalmic SolutionCornea03 medical and health sciencesImmunosuppressive Agent0302 clinical medicineOphthalmologyCorneaMicroscopyCorrespondenceMedicineHumansIn patientOphthalmology; Sensory Systems; Dry Eye; Corneal confocal scanning laser microscopyCorneal confocal scanning laser microscopyMicroscopy Confocalbusiness.industryDry Eyeeye diseasesSensory SystemsOphthalmology030104 developmental biologyOphthalmic solutionsmedicine.anatomical_structure030221 ophthalmology & optometryCyclosporineDry Eye Syndromessense organsOphthalmic SolutionsbusinessImmunosuppressive AgentsHuman
researchProduct

Initial serum thyroid peroxidase antibodies and long-term outcomes in SREAT.

2015

Objective To quantify clinical outcome in patients with steroid-responsive encephalopathy and associated autoimmune thyroiditis (SREAT) after the acute phase and explore potential associations of initial serum thyroid peroxidase antibody titers (TPO-Abs) with outcome. Materials and methods Retrospective chart review of patients diagnosed with SREAT between 01/2005 and 05/2014 in a tertiary care center and followed in an affiliated autoimmune outpatient clinic. Outcome was quantified using the extended Glasgow Outcome Scale (GOS-E). We calculated Pearson's correlation coefficients to quantify associations with clinical outcome at follow-up. Results Among 134 patients with encephalopathy of u…

0301 basic medicineMaleAnti-Inflammatory AgentsGlasgow Outcome Scaleblood [Iodide Peroxidase]0302 clinical medicineblood [Hashimoto Disease]blood [Encephalitis]Outpatient clinicHashimoto Diseasebiologytherapy [Hashimoto Disease]Glasgow Outcome Scaletherapy [Encephalitis]therapeutic use [Anti-Inflammatory Agents]General MedicineMiddle Agedblood [Thyroiditis Autoimmune]Magnetic Resonance Imagingtherapy [Thyroiditis Autoimmune]Treatment OutcomeNeurologyEncephalitisFemaleSteroidsImmunosuppressive AgentsAdultmedicine.medical_specialtyEncephalopathyHashimoto DiseaseIodide PeroxidaseAutoimmune thyroiditisanalysis [Autoantibodies]03 medical and health sciencesimmunology [Thyroiditis Autoimmune]Thyroid peroxidaseInternal medicinemedicineHumansddc:610immunology [Encephalitis]therapeutic use [Steroids]AgedAutoantibodiesRetrospective Studiesbusiness.industrytherapeutic use [Methotrexate]Thyroiditis AutoimmuneRetrospective cohort studymedicine.diseasetherapeutic use [Immunosuppressive Agents]immunology [Hashimoto Disease]030104 developmental biologyMethotrexateImmunologybiology.proteinEtiologyNeurology (clinical)businessimmunology [Iodide Peroxidase]030217 neurology & neurosurgeryFollow-Up StudiesActa neurologica Scandinavica
researchProduct

Lamivudine/Adefovir Treatment Increases the Rate of Spontaneous Mutation of Hepatitis B Virus in Patients.

2016

The high levels of genetic diversity shown by hepatitis B virus (HBV) are commonly attributed to the low fidelity of its polymerase. However, the rate of spontaneous mutation of human HBV in vivo is currently unknown. Here, based on the evolutionary principle that the population frequency of lethal mutations equals the rate at which they are produced, we have estimated the mutation rate of HBV in vivo by scoring premature stop codons in 621 publicly available, full-length, molecular clone sequences derived from patients. This yielded an estimate of 8.7 × 10-5 spontaneous mutations per nucleotide per cell infection in untreated patients, which should be taken as an upper limit estimate becau…

0301 basic medicineMaleRNA virusesMutation ratelcsh:Medicinemedicine.disease_causeBiochemistryPolymerasesAdefovirFrameshift Mutationlcsh:SciencePathology and laboratory medicineeducation.field_of_studyMultidisciplinaryMicrobial MutationLamivudineMedical microbiologyResistance mutation3. Good healthLamivudineVirusesFemalePathogensSequence AnalysisImmunosuppressive Agentsmedicine.drugResearch ArticleHepatitis B virusSubstitution MutationPopulationOrganophosphonatesBiologyResearch and Analysis MethodsPolymorphism Single NucleotideMicrobiologyFrameshift mutation03 medical and health sciencesHepatitis B ChronicDrug Resistance ViralDNA-binding proteinsmedicineGeneticsHumanseducationMolecular Biology TechniquesSequencing TechniquesMolecular BiologyHepatitis B virusMedicine and health sciencesPoint mutationAdeninelcsh:RViral pathogensOrganismsBiology and Life SciencesProteinsVirologyMolecular biologyHepatitis virusesMicrobial pathogens030104 developmental biologyMutationlcsh:QCloningPLoS ONE
researchProduct

Renal tubular epithelial cell-derived BAFF expression mediates kidney damage and correlates with activity of proliferative lupus nephritis in mouse a…

2017

B-cell activating factor of the tumour necrosis factor family (BAFF) is a cytokine, mainly produced by hematopoietic cells (e.g. monocytes/macrophages, dendritic cells), indispensable for B-cell maturation. The BLISS studies have demonstrated that blocking BAFF by the human monoclonal antibody belimumab is a valuable therapeutic approach in patients with clinically and serologically active systemic lupus erythematosus (SLE). However, the defined sources of BAFF, which contributes to SLE, are still unclear. Recent findings show that BAFF expression is not restricted to myeloid cells. Since lupus nephritis is the main cause of morbidity and mortality for SLE patients, the aim of this study wa…

0301 basic medicineMalemedicine.medical_treatmentLupus nephritisAntibodies Monoclonal HumanizedKidneySeverity of Illness IndexPathogenesis03 medical and health sciencesMice0302 clinical medicinestomatognathic systemRheumatologyimmune system diseasesB-Cell Activating FactormedicineAnimalsHumansLupus Erythematosus Systemicskin and connective tissue diseasesB-cell activating factorAutocrine signallingRetrospective StudiesB-Lymphocytesbusiness.industryTumor Necrosis Factor-alphaEpithelial Cellsmedicine.diseaseBelimumabLupus Nephritisstomatognathic diseasesHaematopoiesis030104 developmental biologyCytokineReceptors Granulocyte-Macrophage Colony-Stimulating FactorImmunologyCytokinesTumor necrosis factor alphaFemaleKidney DiseasesbusinessImmunosuppressive Agents030215 immunologymedicine.drugLupus
researchProduct

Parvovirus B19V Nonstructural Protein NS1 Induces Double-Stranded Deoxyribonucleic Acid Autoantibodies and End-Organ Damage in Nonautoimmune Mice

2018

Abstract Background Viral infection is implicated in development of autoimmunity. Parvovirus B19 (B19V) nonstructural protein, NS1, a helicase, covalently modifies self double-stranded deoxyribonucleic acid (dsDNA) and induces apoptosis. This study tested whether resulting apoptotic bodies (ApoBods) containing virally modified dsDNA could induce autoimmunity in an animal model. Methods BALB/c mice were inoculated with (1) pristane-induced, (2) B19V NS1-induced, or (3) staurosporine-induced ApoBods. Serum was tested for dsDNA autoantibodies by Crithidia luciliae staining and enzyme-linked immunosorbent assay. Brain, heart, liver, and kidney pathology was examined. Deposition of self-antigens…

0301 basic medicinePathogenesis and Host ResponseviruksetvirusesB19VKidney GlomerulusSLEApoptosisAutoimmunityanti-dsDNA antibodyViral Nonstructural Proteinsmedicine.disease_causeAutoimmunityautoimmuniteettiMice0302 clinical medicineGlomerulonephritisParvovirus B19 HumanImmunology and Allergy030212 general & internal medicineEnzyme InhibitorstolerancebiologyChemistryapoptosisBrainInfectious DiseasesLivervirustauditAntibodies AntinuclearmaksatulehdusFemaleAntibodyImmunosuppressive Agentsta3111infektiot03 medical and health sciencesohjelmoitunut solukuolemaMajor Articles and Brief ReportsExtracellular VesiclesAntigenmedicineCrithidia luciliaeAnimalsapoptotic bodiesparvoviruksetParvovirusTerpenesAnti-dsDNA antibodiesMyocardiumta1183parvovirusAutoantibodyta1182DNAbiology.organism_classificationStaurosporineMolecular biology030104 developmental biologyApoptosisbiology.proteinautovasta-aineetglomerulonephritisThe Journal of Infectious Diseases
researchProduct

Autophagy Stimulation as a Potential Strategy Against Intestinal Fibrosis

2019

We recently observed reduced autophagy in Crohn’s disease patients and an anti-inflammatory effect of autophagy stimulation in murine colitis, but both anti- and pro-fibrotic effects are associated with autophagy stimulation in different tissues, and fibrosis is a frequent complication of Crohn’s disease. Thus, we analyzed the effects of pharmacological modulation of autophagy in a murine model of intestinal fibrosis and detected that autophagy inhibition aggravates, while autophagy stimulation prevents, fibrosis. These effects are associated with changes in inflammation and in collagen degradation in primary fibroblasts. Thus, pharmacological stimulation of autophagy may be useful against …

0301 basic medicineautophagyStimulationInflammationDiseaseIntestinal fibrosis03 medical and health sciencesMice0302 clinical medicineCrohn DiseaseFibrosismedicineintestinal fibrosisMurine colitisAnimalslcsh:QH301-705.5Sirolimusbusiness.industryBrief ReportAutophagyGeneral MedicineFibroblastsmedicine.diseaseFibrosisIntestinesMice Inbred C57BLDisease Models Animal030104 developmental biologylcsh:Biology (General)inflammationCancer research030211 gastroenterology & hepatologyCollagenmedicine.symptomComplicationbusinessImmunosuppressive AgentsCells
researchProduct

Interstitial lung disease in systemic sclerosis: current and future treatment.

2017

Systemic sclerosis (SSc) has the highest fatality rate among connective tissue diseases and is characterized by vascular damage, inflammation and fibrosis of the skin and various internal organs. Interstitial lung disease (ILD) frequently complicates SSc and can be a debilitating disorder with a poor prognosis. ILD is the most frequent cause of death in SSc, and the management of SSc–ILD patients is a great challenge. Early detection of pulmonary involvement based on a recent decline of lung function tests and on the extent of lung involvement at high-resolution computed tomography is critical for the best management of these patients. This article summarizes classification, pathogenesis,…

0301 basic medicinemedicine.medical_specialtyPathologyFibrosiImmunologyInterstitial lung diseaseSclerodermaPulmonary function testingSclerodermaPathogenesis03 medical and health sciencesSystemic sclerosi0302 clinical medicineRheumatologyFibrosisPredictive Value of TestsRisk FactorsInternal medicineCase fatality ratemedicineAnimalsHumansImmunology and AllergyMolecular Targeted Therapyskin and connective tissue diseasesLungCause of death030203 arthritis & rheumatologyScleroderma Systemicintegumentary systembusiness.industryInterstitial lung diseaseHematopoietic Stem Cell Transplantationrespiratory systemmedicine.diseaseRheumatologyRespiratory Function Testsrespiratory tract diseasesTreatmentSettore MED/16 - Reumatologia030104 developmental biologyEarly DiagnosisTreatment OutcomebusinessLung Diseases InterstitialTomography X-Ray ComputedImmunosuppressive AgentsLung Transplantation
researchProduct